瑞舒伐他汀联合荷丹片治疗急性脑梗死及对Copeptin、NT-proBNP水平变化研究

Rosuvastatin combined with Hedan tablets in treatment of acute cerebral infarction and effect on levels of copeptin and NT-proBNP

摘要:

目的  研究瑞舒伐他汀联合荷丹片治疗急性脑梗死的临床疗效及其对Copeptin、N端脑钠肽原（NT-proBNP）水平的影响。方法  选取2013年3月-2015年4月于该院接受治疗的急性脑梗死患者93例。根据随机数字表分为对照组和治疗组，对照组给予瑞舒伐他汀片治疗，治疗组口服瑞舒伐他汀，同时服用荷丹片。结果  两组患者治疗总有效率比较，差异无统计学意义（χ2=2.461，P =0.117）。治疗后治疗组患者低密度脂蛋白（LDL-C）水平低于对照组，差异有统计学意义（t =2.318，P =0.023），治疗组患者高密度脂蛋白水平高于对照组，差异有统计学意义（t =2.784，P =0.007）。治疗组LDL-C水平达标率高于对照组，差异有统计学意义（χ2=4.301，P =0.038）；对照组不良反应总发生率高于治疗组，差异有统计学意义（χ2=4.301，P =0.038）。治疗后，治疗组患者Copeptin和NT-proBNP水平均低于对照组，差异有统计学意义（P <0.05）。结论  瑞舒伐他汀联合荷丹片对急性脑梗死的临床疗效与大剂量瑞舒伐他汀相当，但不良反应发生率降低，安全性更高。同时可能有利于改善急性脑梗死患者的预后。

Abstract:

Objective To study the effect of Rosuvastatin combined Hedan tablets on treatment of acute cerebral infarction and its influence on the levels of copeptin and N-terminal pro-brain natriuretic peptide (NT-proBNP). Methods Ninety-three patients with acute cerebral infarction treated in our hospital from March 2013 to April 2015 were divided into treatment group and control group according to the random number table. The control group received Rosuvastatin tablets, the treatment group was treated with Rosuvastatin and Hedan tablets. Results There was no significant difference in the total effective rate between the two groups (χ2 = 2.461, P = 0.117). The level of LDL-C in the treatment group was significantly lower than that in the control group (t = 2.318, P = 0.023), and the The level of HDL-C in the treatment group was significantly higher than that in the control group (t = 2.784, P = 0.007). The rate of the patients with standard LDL-C level in the treatment group was significantly higher than that in the control group (χ2 = 4.301, P = 0.038). The total incidence of adverse reactions in the control group was significantly higher than that in the treatment group (χ2 = 4.301, P = 0.038). After treatment, the copeptin and NT-proBNP levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusions Rosuvastatin combined Hedan tablets has similar clinical curative effect to large dose of Rosuvastatin in treatment of acute cerebral infarction, but its total incidence of adverse reactions is significantly reduced, and has higher security. At the same time, it maybe improve the prognosis of patients.